St2 antigen binding proteins
US-2024368292-A1 · Nov 7, 2024 · US
US10696747B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10696747-B2 |
| Application number | US-201816112008-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2018 |
| Priority date | Aug 6, 2015 |
| Publication date | Jun 30, 2020 |
| Grant date | Jun 30, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
Opening claim text (preview).
The invention claimed is: 1. An isolated antibody or antigen binding fragment which specifically binds to common γ chain (γc), and comprises: (i) a light chain variable region comprising the following CDRs: LC-CDR1: (SEQ ID NO: 68) RSSQSLLHSNGYNYLD LC-CDR2: (SEQ ID NO: 69) LGSNRDS LC-CDR3: (SEQ ID NO: 70) MQGTHWPWT; and (ii) a heavy chain variable region comprising the following CDRs: HC-CDR1: (SEQ ID NO: 48) GYYWS HC-CDR2: (SEQ ID NO: 49) EINHSGSTNYNPSLKS HC-CDR3: (SEQ ID NO: 77) SPGGYSGGYFQH. 2. The isolated antibody or antigen binding fragment according to claim 1 , wherein: the light chain variable region sequence has at least 70% sequence identity to SEQ ID NO:67, and the heavy chain variable region sequence has at least 70% sequence identity to SEQ ID NO:76. 3. The isolated antibody or antigen binding fragment according to claim 1 , wherein: the light chain variable region sequence has at least 85% sequence identity to SEQ ID NO:67, and the heavy chain variable region sequence has at least 85% sequence identity to SEQ ID NO:76. 4. The isolated antibody or antigen binding fragment according to claim 1 , conjugated to a drug moiety or a detectable moiety. 5. A bispecific antibody comprising the antibody or antigen binding fragment of claim 1 .
Retroviridae (F), e.g. leukemia viruses · CPC title
Natural killers cells [NK], NKT cells · CPC title
T lymphocytes · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
against receptors for cytokines, lymphokines, interferons · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.